Skip to content
The Nexus
DossierENTITY

Karyopharm Therapeutics Inc.

Coverage of Karyopharm Therapeutics Inc. in the Nexus archive.

Earliest in view: Aug 13 · 11:49 UTCMost recent: Aug 13 · 11:49 UTC
Co-mentioned in this coverage
Newtonplace1Mass.place1$67 milliontopic1$2.32 per sharetopic1$33.4 milliontopic1
Recent coverage
  • BUSINESSAug 13 · 11:49 UTCWTOP DC
    Karyopharm Therapeutics: Q2 Earnings Snapshot

    Karyopharm Therapeutics reported a loss of $67 million and $2.32 per share in its second quarter. The company posted revenue of $33.4 million during the period and anticipates full-year revenue between $130 million to $150 million.

Karyopharm Therapeutics Inc. · Dossier · The Nexus